Massive data review reveals how well Dose-Dense chemo works for early breast cancer
NCT ID NCT07521397
First seen Apr 10, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study combined data from over 5,300 early-stage breast cancer patients to see how well dose-dense sequential chemotherapy works over the long term. Researchers looked at how long patients stayed cancer-free and overall survival, as well as side effects. The goal was to better understand the benefits and risks of this treatment approach for people with intermediate or high-risk breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Athens, 11526, Greece
Conditions
Explore the condition pages connected to this study.